$13.32
0[0.00%]
At close: Apr 23
$13.32
0[0.00%]
After Hours: 4:00PM EDT
Cabaletta Bio
(NASDAQ:CABA)Cabaletta Bio Stock (NASDAQ:CABA), Analyst Ratings, Price Targets, Predictions
Cabaletta Bio Inc has a consensus price target of $26.5, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Citigroup, and Cantor Fitzgerald on April 5, 2024, April 4, 2024, and March 22, 2024. With an average price target of $43.33 between Cantor Fitzgerald, Citigroup, and Cantor Fitzgerald, there's an implied 225.33% upside for Cabaletta Bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Citigroup
Wells Fargo
HC Wainwright & Co.
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cabaletta Bio
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | CABA | Buy Now | Cabaletta Bio | $13.32 | 275.38% | Cantor Fitzgerald | Joshua Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 04/04/2024 | CABA | Buy Now | Cabaletta Bio | $13.32 | 125.23% | Citigroup | Samantha Semenkow | $26 → $30 | Maintains | Buy | Get Alert |
| 03/22/2024 | CABA | Buy Now | Cabaletta Bio | $13.32 | 275.38% | Cantor Fitzgerald | Joshua Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | CABA | Buy Now | Cabaletta Bio | $13.32 | 162.76% | Wells Fargo | Derek Archila | $34 → $35 | Maintains | Overweight | Get Alert |
| 03/22/2024 | CABA | Buy Now | Cabaletta Bio | $13.32 | 125.23% | HC Wainwright & Co. | Douglas Tsao | $25 → $30 | Maintains | Buy | Get Alert |
| 02/05/2024 | CABA | Buy Now | Cabaletta Bio | $13.32 | 170.27% | Jefferies | Kelly Shi | → $36 | Initiates | → Buy | Get Alert |
| 11/29/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 87.69% | Morgan Stanley | Michael Ulz | $28 → $25 | Maintains | Overweight | Get Alert |
| 11/29/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 87.69% | HC Wainwright & Co. | Douglas Tsao | → $25 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 275.38% | Cantor Fitzgerald | Joshua Schimmer | $40 → $50 | Maintains | Overweight | Get Alert |
| 11/10/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 87.69% | HC Wainwright & Co. | Douglas Tsao | $17 → $25 | Maintains | Buy | Get Alert |
| 11/08/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 110.21% | Morgan Stanley | Michael Ulz | $16 → $28 | Maintains | Overweight | Get Alert |
| 10/24/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 200.3% | Cantor Fitzgerald | Joshua Schimmer | → $40 | Initiates | → Overweight | Get Alert |
| 10/19/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 132.73% | Stifel | Ben Burnett | → $31 | Initiates | → Buy | Get Alert |
| 10/04/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 27.63% | HC Wainwright & Co. | Douglas Tsao | → $17 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 192.79% | Wells Fargo | Derek Archila | $14 → $39 | Maintains | Overweight | Get Alert |
| 09/05/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 65.17% | Citigroup | Samantha Semenkow | → $22 | Initiates | → Buy | Get Alert |
| 08/14/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 155.26% | Guggenheim | Yatin Suneja | → $34 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 27.63% | HC Wainwright & Co. | Douglas Tsao | $15 → $17 | Maintains | Buy | Get Alert |
| 07/18/2023 | CABA | Buy Now | Cabaletta Bio | $13.32 | 155.26% | Guggenheim | Yatin Suneja | → $34 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cabaletta Bio (CABA)?
The latest price target for Cabaletta Bio (NASDAQ: CABA) was reported by Cantor Fitzgerald on April 5, 2024. The analyst firm set a price target for $50.00 expecting CABA to rise to within 12 months (a possible 275.38% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cabaletta Bio (CABA)?
The latest analyst rating for Cabaletta Bio (NASDAQ: CABA) was provided by Cantor Fitzgerald, and Cabaletta Bio reiterated their overweight rating.
When was the last upgrade for Cabaletta Bio (CABA)?
The last upgrade for Cabaletta Bio Inc happened on January 27, 2023 when Morgan Stanley raised their price target to $16. Morgan Stanley previously had an equal-weight for Cabaletta Bio Inc.
When was the last downgrade for Cabaletta Bio (CABA)?
The last downgrade for Cabaletta Bio Inc happened on August 30, 2022 when Morgan Stanley changed their price target from $15 to $3 for Cabaletta Bio Inc.
When is the next analyst rating going to be posted or updated for Cabaletta Bio (CABA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cabaletta Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cabaletta Bio was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.
Is the Analyst Rating Cabaletta Bio (CABA) correct?
While ratings are subjective and will change, the latest Cabaletta Bio (CABA) rating was a reiterated with a price target of $0.00 to $50.00. The current price Cabaletta Bio (CABA) is trading at is $13.32, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.